WO2008016604A2 - Utilisation de la colostrinine, peptides constitutifs de celle-ci, et leurs analogues comme agents anti-mutagéniques - Google Patents

Utilisation de la colostrinine, peptides constitutifs de celle-ci, et leurs analogues comme agents anti-mutagéniques Download PDF

Info

Publication number
WO2008016604A2
WO2008016604A2 PCT/US2007/017112 US2007017112W WO2008016604A2 WO 2008016604 A2 WO2008016604 A2 WO 2008016604A2 US 2007017112 W US2007017112 W US 2007017112W WO 2008016604 A2 WO2008016604 A2 WO 2008016604A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
colostrinin
cell
induced
constituent peptide
Prior art date
Application number
PCT/US2007/017112
Other languages
English (en)
Other versions
WO2008016604A3 (fr
Inventor
Marian Kruzel
Istvan Boldogh
Original Assignee
Board Of Regents, The University Of Texas System
Regen Therapeutics Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Regents, The University Of Texas System, Regen Therapeutics Plc filed Critical Board Of Regents, The University Of Texas System
Publication of WO2008016604A2 publication Critical patent/WO2008016604A2/fr
Publication of WO2008016604A3 publication Critical patent/WO2008016604A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor

Definitions

  • Colostrum is a component of the milk of mammals during the first few days after birth. Colostrum is a thick yellowish fluid, is the first lacteal secretion post parturition and contains a high concentration of immunogloblins (IgG, IgM, and IgA) and a variety of proteins with unknown functions. Colostrum also contains various cells such as granular and stromal cells, neutrophils, monocyte/ macrophages, and lymphocytes and includes growth factors, hormones, and cytokines. Unlike mature breast milk, colostrum contains low sugar, low iron, but is rich is lipids, proteins, mineral salts, vitamins, and immunoglobins.
  • immunogloblins IgG, IgM, and IgA
  • Colostrum also contains various cells such as granular and stromal cells, neutrophils, monocyte/ macrophages, and lymphocytes and includes growth factors, hormones, and cytokines.
  • colostrum contains low sugar, low iron, but is rich is lipid
  • Colostrum also includes a proline-rich polypeptide aggregate or complex, which is referred to as colostrinin (CLN).
  • CLN proline-rich polypeptide aggregate or complex
  • One peptide fragment of colostrinin is Val-Glu-Ser-Tyr-Val-Pro-Leu-Phe-Pro (SEQ ID NO:31).
  • Colostrinin and this fragment have been identified as useful in the treatment of disorders of the central nervous system, neurological disorders, mental disorders, dementia, neurodegenerative diseases, Alzheimer's disease, motor neuron disease, psychosis, neurosis, chronic disorders of the immune system, diseases with a bacterial and viral etiology, and acquired immunological deficiencies, as set forth in International Publication No. WO 98/14473. Although certain uses for colostrinin have been identified, it would represent advancement in the art to discover and disclose other uses for colostrinin and constituent peptides thereof.
  • the present invention includes a method of decreasing the mutation frequency in a cell, the method including contacting the cell with a modulator selected from the group of colostrinin, a constituent peptide of colostrinin, an active analog of a constituent peptide of colostrinin, and combinations thereof.
  • the present invention includes a method of decreasing the mutation frequency in a cell, the method including contacting the cell with a modulator selected from the group of colostrinin, a constituent peptide of colostrinin, an active analog of a constituent peptide of colostrinin, and combinations thereof, under conditions effective to accomplish at least one of the following: decrease the frequency of reactive oxygen-species (ROS) induced mutations; decrease the frequency of mutations induced by chemical agents; or decrease the frequency of mutations induced by physical agents.
  • a modulator selected from the group of colostrinin, a constituent peptide of colostrinin, an active analog of a constituent peptide of colostrinin, and combinations thereof, under conditions effective to accomplish at least one of the following: decrease the frequency of reactive oxygen-species (ROS) induced mutations; decrease the frequency of mutations induced by chemical agents; or decrease the frequency of mutations induced by physical agents.
  • ROS reactive oxygen-species
  • the present invention includes a method of decreasing the mutation frequency in a cell, the method including contacting the cell with a modulator selected from the group of colostrinin, a constituent peptide of colostrinin, an active analog of a constituent peptide of colostrinin, and combinations thereof; wherein the mutation frequency is induced by chemical agents and/or physical agents and is not induced by reactive oxygen-species (ROS).
  • a modulator selected from the group of colostrinin, a constituent peptide of colostrinin, an active analog of a constituent peptide of colostrinin, and combinations thereof; wherein the mutation frequency is induced by chemical agents and/or physical agents and is not induced by reactive oxygen-species (ROS).
  • ROS reactive oxygen-species
  • the present invention includes a method of decreasing the mutation frequency in a cell, the method including contacting the cell with a modulator selected from the group of colostrinin, a constituent peptide of colostrinin, an active analog of a constituent peptide of colostrinin, and combinations thereof; wherein the mutation frequency is induced not only by reactive oxygen-species (ROS), but is also induced also by chemical agents and/or physical agents.
  • ROS reactive oxygen-species
  • the present invention includes a method of decreasing the mutation frequency in a cell, the method including contacting the cell with a modulator selected from the group of colostrinin, a constituent peptide of colostrinin, an active analog of a constituent peptide of colostrinin, and combinations thereof; wherein the mutation frequency is induced by a chemical agent and/or a physical agent and is not induced by UVA or UVB radiation.
  • the present invention includes a method of decreasing the mutation frequency in a cell, the method including contacting the cell with a modulator selected from the group of colostrinin, a constituent peptide of colostrinin, an active analog of a constituent peptide of colostrinin, and combinations thereof; wherein the mutation frequency is UVA radiation-induced mutagenesis.
  • the present invention includes a method of decreasing the mutation frequency in a cell, the method including contacting the cell with a modulator selected from the group of colostrinin, a constituent peptide of colostrinin, an active analog of a constituent peptide of colostrinin, and combinations thereof; wherein the mutation frequency is UVB radiation-induced mutagenesis.
  • the present invention includes a method of decreasing the mutation frequency in a cell, the method including contacting the cell with a modulator selected from the group of colostrinin, a constituent peptide of colostrinin, an active analog of a constituent peptide of colostrinin, and combinations thereof; wherein the mutation frequency is induced by a chemical agent.
  • the present invention includes a method of decreasing the mutation frequency in a cell, the method including contacting the cell with a modulator selected from the group of colostrinin, a constituent peptide of colostrinin, an active analog of a constituent peptide of colostrinin, and combinations thereof; wherein the mutation frequency is induced by a physical agent.
  • the present invention includes a method of decreasing spontaneous mutation frequency in a cell, the method including contacting the cell with a modulator selected from the group of colostrinin, a constituent peptide of colostrinin, an active analog of a constituent peptide of colostrinin, and combinations thereof.
  • the present invention includes a method of decreasing mutation frequency in a cell, the method including contacting the cell with a modulator selected from the group of colostrinin, a constituent peptide of colostrinin, an active analog of a constituent peptide of colostrinin, and combinations thereof, wherein the mutation frequency is environmentally induced.
  • the present invention includes a method of decreasing the mutation frequency in a cell, the method including contacting the cell with a modulator selected from the group of colostrinin, a constituent peptide of colostrinin, an active analog of a constituent peptide of colostrinin, and combinations thereof; wherein the modulator is administered in conjunction with one or more therapeutic agents that induce mutations in genomic and/or mitochondrial DNA.
  • the therapeutic agent is chemotherapy or radiation therapy for cancer.
  • the modulator is a constituent peptide of colostrinin or an analog thereof.
  • the constituent peptide of colostrinin is selected from the group of MQPPPLP (SEQ ID NO:1), LQTPQPLLQVMMEPQGD (SEQ ID NO:2), DQPPD VEKPDLQPFQ VQS (SEQ ID NO:3), LFFFLPVVNVLP (SEQ ID NO:4), DLEMPVLPVEPFPFV (SEQ ID NO:5) 5 MPQNFYKLPQM (SEQ ID NO:6), VLEMKPPPPPQETVT (SEQ ID NO :7), LKPFPKLKVE VFPFP (SEQ ID NO:8), VVMEV (SEQ ID NO:9), SEQP (SEQ ID NO: 10), DKE (SEQ ID NO:1 1), FPPPK (SEQ ID NO: 12), DSQPPV (SEQ ID NO: 13), DPPPPQS (SEQ ID NO: 14), SEEMP (SEQ ID NO: 15), KYKL
  • TQTPVVVPPF (SEQ ID NO:20), LQPEIMGVPKVKETMVPK (SEQ ID NO:21), HKEMPFPKYPVEPFTESQ (SEQ ID NO:22) S SLTLTDVEKLHLPLPLVQ (SEQ ID NO:23), SWMHQPP (SEQ ID NO:24), QPLPPTVMFP (SEQ ID NO:25), PQSVLS (SEQ ID NO:26), LSQPKVLPVPQKAVPQRDMPIQ (SEQ ID NO:27), AFLLYQE (SEQ ID NO:28), RGPFPILV (SEQ ID NO:29),
  • ATFNRYQDDHGEEILKSL (SEQ ID NO:30), VESYVPLFP (SEQ ID NO.-31), FLLYQEPVLGPVR (SEQ ID NO:32), LNF (SEQ ID NO:33), and MHQPPQPLPPTVMFP (SEQ TD NO:34), RPKHPIKHQGLPQEVLNENLLRF (SEQ ID NO:35), FVAPFPEVFGKEKV (SEQ ID NO:36), SDIPNPIGSENSEKTTMPLW (SEQ ID NO:37), GPVRGPFPI (SEQ ID NO:38), EPVLGPVRGPFPI (SEQ ID NO:39), VPYPQRDMPIQ (SEQ ID NO:40), SLSQSKVLPVPQKAVPYPQRDMPIQ (SEQ ID NO:41), RPKHPIKHQ (SEQ ID NO:42); EPVLGPVR (SEQ ID NO:43); RGPFPIIV (SEQ ID NO:44); PPPPLLPSRPLPPLP
  • an active analog of a constituent peptide of colostrinin comprises a peptide having an amino acid sequence with at least about 15 percent proline and having at least about 70 percent structural similarity to one or more constituent peptides of colostrinin.
  • the cell is present in a cell culture, a tissue, an organ, or an organism.
  • the cell is a mammalian cell.
  • the cell is a human cell.
  • the present invention includes the use of a compound selected from the group of colostrinin, a constituent peptide thereof, an active analog thereof, and combinations thereof in the manufacture of a medicament for reducing the mutation frequency in a cell.
  • FIG. IA shows CLN decreases spontaneous mutation frequency.
  • Parallel cultures of V79 cells were treated with increasing concentrations of CLN for 48 hours (3.6 population doublings (PDs)) in growth medium. Then cells were placed in 10-cm Petri dishes (10 6 cells per dish) in six parallel experiments and incubated further in medium containing 6-Thioguanine (TG) (7 ⁇ g per ml). Seven days later cell colonies were fixed, stained with crystal violet and counted.
  • Fig. IB shows long-term treatment with CLN exerts no mutagenic potential. Cells were maintained with or without CLN (concentrations are as indicated) for ⁇ 40 PDs and mutation frequencies determined.
  • Figures 2 A to 2C demonstrate that CLN decreases frequency of ROS- induced 6-TG resistant cells.
  • Fig. 2A shows the effect of CLN on ROS-induced mutation frequency.
  • Cells were grown in the presence of CLN for 24 hours and then treated with GOx (20 ng per ml) for one hour (at 37 0 C), washed and further incubated for 1 day with CLN.
  • Fig. 2B shows the effect of CLN pre-treatment on MF induced by ROS. Cells were grown for 24 hours in medium containing CLN, and GOx-treated as above, washed and further incubated for one day without CLN.
  • Fig. 2C shows the effect of post-treatment with CLN on ROS-induced mutation frequency.
  • Figs. 2A- 2C Cells were grown without CLN, GOx-treated as in Fig. 2A, washed, and incubated further for an additional 24 hours in the presence of CLN.
  • Figs. 2A- 2C cells were trypsinized, counted and seeded in 6-TG containing medium (10 6 cells per 10 cm dish). Seven days later colonies were stained, and counted and mutation frequencies were calculated (Bradley et al., 1981, Mutat Res, 87-81-142; Albrecht et al., 1997, Virology, 230:48-61).
  • Figures 3 A and 3B show the effect of CLN on UVA- and UVB-induced mutation frequency.
  • Fig. 3 A shows the frequency of hprt mutations in UVA- irradiated cells ⁇ CLN. Cells were grown ⁇ CLN for 24 hours and at 50% confluence irradiated with UVA (87 kJ per m 2 ), and CLN-containing media were added back. At 24 hours later cells were placed (10 6 cells per dish) in 6-TG-containing selection medium.
  • Fig. 3B shows CLN exerts protection against UVB-induced mutations. Experiments were carried out as in Fig. 3 A, but cells were irradiated with UVB (4.1 kJ per m 2 ). In Figs. 3A and 3B, mutation frequencies were calculated as in the legend to Fig. 1.
  • Figures 4A and 4B show the effect of CLN on frequency of 6-TG-resistant mutants in alkylating agent-treated cell cultures.
  • Fig. 4A shows the change in MF by CLN in MMS-treated cells.
  • Fig. 4B shows decreased MF by CLN in MMC-treated cells. Experiments were undertaken as above in Fig. 4A, but cells were MMC-treated. In Figs. 4A and 4B, mutation frequencies were determined as in the legend to Fig. 1.
  • Figure 5 shows that CLN decreases mutation frequency in human cells at the hprt locus.
  • Human airway epithelial cell cultures at 50% confluence were treated with CLN (250, 500 ng per ml) for 24 hours and then exposed to GOx (110 ng per ml for one hour); UVA ( 105 kJ per m 2 ), UVB (7.1 kJ per m 2 ) or MMC (53 ⁇ M for one hour). Cells were washed and growth medium containing CLN was added to the corresponding cultures for 52 h (two PDs). Mutation frequencies were determined as in the legend to Fig. 1.
  • Colostrinin a complex of proline-rich polypeptides derived from colostrum, induces various signaling pathways common to cell proliferation and differentiation, and mediates events similar to those of hormones and neurotrophins, leading to neurite outgrowth (see, for example, Bacsi et al. Cell MoI Neurobiol 25: 1 123-1 139, 2005; U.S. Patent No. 6,852,685; and WO 02/13852).
  • CLN is an important immune-modulator; it has been shown to induce various cytokines, mediate maturation and differentiation of murine thymocytes (see, for example, Janusz et al.
  • CLN decreases the intracellular oxidative stress levels, and reduces 4-hydroxynonenal (4HNE)-mediated cellular damage and cellular signaling in cultured cells
  • 4HNE 4-hydroxynonenal
  • CLN protects neuroblastoma cells from beta amyloid-induced apoptosis by inhibiting amyloid aggregation (Schuster et al. Neuropeptides 39: 419-426, 2005). Most importantly, CLN administration to Alzheimer's patients resulted in stabilization of cognitive functions and improvement in the ability to perform routine domestic functions (see, for example, Bilikiewicz et al. J Alzheimers Dis 6: 17-26, 2004, Leszek et al. Arch Immunol Ther Exp (Warsz) 47: 377-385, 1999).
  • colostrinin, constituent peptides of colostrinin, and analogs of constituent peptides can be used as modulators of mutation frequencies (MF). More specifically, colostrinin, constituent peptides of colostrinin, and analogs of constituent peptides modulate mutation frequency by decreasing or reducing mutation frequency.
  • a mutation is a permanent alteration in the sequence of nitrogenous bases of a DNA molecule. The result of a mutation may be a change in the end-product specified by that gene.
  • a mutation can be beneficial if a new metabolic activity arises in a microorganism, or it can be detrimental if a metabolic activity is altered or lost.
  • Mutation frequencies may be determined by any of many known methods, including, but not limited to, any of those described herein. Mutations may include somatic mutations and/or germline mutations. Somatic mutations occur in a somatic cell, for example, the bone marrow or liver, may make the cell cancerous, and/or may kill the cell. Whatever the effect, the ultimate fate of a somatic mutation is to disappear when the cell in which it is present dies. Germline mutations, in contrast, may be found in every cell descended from the zygote in which the mutant gamete contributed.
  • Mutations may include genomic and/or mitochondrial mutations. Mutations may include spontaneous mutations, environmentally induced mutations and/or mutations induced by the administration of another agent, for example, the administration of a therapeutic agent for the treatment of a disease, such as, for example, a chemotherapeutic agent or radiation.
  • the present invention provides methods of decreasing the mutation frequency in a cell by contacting the cell with a modulator selected from the group of colostrinin, a constituent peptide of colostrinin, an active analog of a constituent peptide of colostrinin, and combinations thereof.
  • a cell may be contacted with a modulator under conditions effective to accomplish one or more of the following: decrease the frequency of reactive oxygen-species (ROS) induced mutations; decrease the frequency of mutations induced by chemical agents; or decrease the frequency of mutations induced by physical agents.
  • ROS reactive oxygen-species
  • the present invention includes methods of decreasing the frequency of mutations induced by reactive oxygen-species, chemical agents, and physical agents; methods of decreasing the frequency of mutations induced by reactive oxygen-species and chemical agents; methods of decreasing the frequency of mutations induced by reactive oxygen-species and physical agents; methods of decreasing the frequency of mutations induced by chemical agents and physical agents; methods of decreasing the frequency of mutations induced by reactive oxygen-species; methods of decreasing the frequency of mutations induced by chemical agents; and methods of decreasing the frequency of mutations induced by physical agents.
  • the present invention also provides methods of decreasing the mutation frequency in a cell wherein the mutation frequency is induced by chemical agents and/or physical agents and is not induced by reactive oxygen-species (ROS).
  • ROS reactive oxygen-species
  • Reactive oxygen species or free radicals are chemical species that have a single unpaired electron in an outer orbit. They are highly reactive chemical radicals that are generated as products of oxygen degradation. Reactive oxygen species include, for example, oxygen ions, free radicals and both inorganic and organic peroxides. They are generally very small molecules and are highly reactive due to the presence of unpaired valence shell electrons. ROSs form as a natural byproduct of the normal metabolism of oxygen and have important roles in cell signaling. However, during times of environmental stress ROS levels can increase dramatically, which can result in significant damage to cell structures. This cumulates into a situation known as oxidative stress. Reactive oxygen species are potent oxidants that can attack chromosomal DNA and free nucleotides, leading to oxidative DNA damage that causes genetic alterations.
  • a cell may be contacted with a modulator under conditions effective to accomplish one or more of the following: decrease the frequency of UVA radiation-induced mutations; decrease the frequency of UVB radiation-induced mutations; decrease the frequency of mutations induced by chemical agents; and/or decrease the frequency of mutations induced by physical agents.
  • the present invention includes methods of decreasing the frequency of mutations induced by UVA irradiation, UVB irradiation, chemical agents, and physical agents; methods of decreasing the frequency of mutations induced by UVA irradiation, chemical agents and physical agents; methods of decreasing the frequency of mutations induced by UVB irradiation, chemical agents and physical agents; methods of decreasing the frequency of mutations induced by UVB irradiation; methods of decreasing the frequency of mutations induced by UVA irradiation; methods of decreasing the frequency of mutations induced by chemical agents and physical agents; methods of decreasing the frequency of mutations induced by chemical agents; and methods of decreasing the frequency of mutations induced by physical agents.
  • the present invention also provides methods of decreasing the mutation frequency wherein the mutation frequency is not induced by UVB irradiation; methods of decreasing the mutation frequency wherein the mutation frequency is not induced by UVA irradiation; and methods of decreasing the mutation frequency wherein the mutation frequency is not induced by UVA irradiation or UVB irradiation.
  • UV light is electromagnetic radiation with a wavelength shorter than that of visible light, but longer than soft X-rays.
  • the sun emits ultraviolet radiation in the UVA, UVB, and UVC bands, but because of absorption in the atmosphere's ozone layer, 99% of the ultraviolet radiation that reaches the Earth's surface is UVA.
  • UVA radiation is that portion of the electromagnetic spectrum from 400 to 320 nanometers (ran).
  • UVB radiation is that portion of the electromagnetic spectrum from 290 to 320 ran.
  • a wide variety of chemical agents that induce genetic mutations are known in the art, including, for example, base analogs (such as, for example, 5- bromouracil), acridines (such as, for example, 2,8,-diamine acridine, also known as proflavin), alkylating agents (such as, for example, N-ethyl-N-nitrosourea (ENU) and ethyl methanesulfonate (EMS)), DNA intercalating agents (such as, for example, ethidium bromide), and DNA cross linkers (such as, for example, mitomycin C (MMC) and platinum).
  • base analogs such as, for example, 5- bromouracil
  • acridines such as, for example, 2,8,-diamine acridine, also known as proflavin
  • alkylating agents such as, for example, N-ethyl-N-nitrosourea (ENU) and ethyl methanesulfonate
  • the present invention also provides methods of decreasing spontaneous mutation frequencies and environmentally induced mutations frequencies.
  • cells may be contacted with one or more modulators in vitro or and in vivo.
  • colostrinin, a constituent peptide of colostrinin, an active analog of a constituent peptide of colostrinin, or combinations thereof may be used to reduce the frequency of mutations induced by any combination of one or more of the various mechanisms by which genetic mutations are induced; for example, reduce the frequency of mutations induced by reactive oxygen species (ROS), exposure to chemical agents, and exposure to physical agents; reduce the frequency of mutations induced by chemical agents and/or physical agents; reduce the frequency of mutations induced by reactive oxygen species (ROS); reduce the frequency of mutations induced by chemical agents; reduce the frequency of mutations induced by physical agents; reduce the frequency of mutations induced by chemical agents and/or physical agent but not the frequency of mutations induced by reactive oxygen species (ROS); reduce the frequency of mutations induced by reactive oxygen species (ROS),
  • Colostrinin is a uniform, low-molecular weight, proline-rich mix of peptides purified from colostrum via various chromatographic steps, including ion exchange, affinity and molecular sieving, (see, for example, Janusz et al. Arch
  • CLN When compared with the original material, CLN shows a characteristic pattern of peptides in SDS PAGE and an amino acid analysis characterized by high content of proline (22%), a high proportion of nonpolar amino acids, a low percentage of glycine, alanine, arginine, histidine, and no tryptophan, methionine, and cysteine residues, a similar pattern of HPLC profiles, and the ability to induce IFN gamma and TNF alpha.
  • CLN is composed of peptides, the aggregate of which has a molecular weight range between about 5.8 to about 26 kilodaltons (kDa) determined by polyacrylamide gel electrophoresis. It has a greater concentration of proline than any other amino acid.
  • CLN may also be referred to as "colostrinin complex” "proline rich polypeptide, "PRP,” “proline-rich polypeptide aggregate,” “proline- rich polypeptide aggregate derived from colostrum,” a “proline-rich polypeptide complex,” a “proline-rich polypeptide complex derived from colostrum,” and “neuroprotective proline-rich polypeptides.”
  • Ovine colostrinin has been found to have a molecular weight of about 18 kDa (Kruzel et al., J. MoI. Neurosci. 17:379- 89, 2001) and includes three non-covalently linked subunits having a molecular weight of about 6 kDa and has about 22% proline by weight.
  • the anti-mutagenic agent is a constituent peptide of colostrinin.
  • Constituent peptides of clostrinin include a number of peptides ranging from about 3 amino acids to about 22 amino acids or more. These can be obtained by various known techniques, including isolation and purification involving electrophoresis or synthetic techniques. Methods of obtaining colostrinin, include, but are not limited to, those described, for example, in WO 98/14473, WO 04/081038, US Patent Application 2005/0085422, and US Patent Application 2006/0154871.
  • MQPPPLP SEQ ID NO:1
  • LQTPQPLLQVMMEPQGD SEQ ID NO:2
  • DQPPDVEKPDLQPFQVQS SEQ ID NO:3
  • LFFFLPVVNVLP SEQ ID NO:4
  • DLEMPVLPVEPFPFV SEQ ID NO:5
  • MPQNFYKLPQM SEQ ID NO:6
  • VLEMKFPPPP QETVT SEQ ID NO:7
  • LKPFPKLKVEVFPFP SEQ ID NO:8
  • VVMEV SEQ ID NO:9
  • SEQP SEQ ID NO: 10
  • DKE SEQ ID NO:11
  • FPPPK SEQ ID NO: 12
  • DSQPPV SEQ ID NO: 13
  • DPPPPQS SEQ ID NO: 14
  • SEEMP SEQ ID NO: 9
  • those of unknown precursor include SEQ ID NOs:2, 6, 7, 8, 10, 1 1, 14, and 33;
  • those having a ⁇ -casein homologue precursor include SEQ ID NOs: 1, 3, 4, 5, 9, 12, 13, 15, 16, 17, and 31;
  • those having a ⁇ -casein precursor include SEQ ID NOs: 18 (casein amino acids 74-83), 19 (casein amino acids 84-92), 20 (casein amino acids 93-102), 21 (casein amino acids 103-120), 22 (casein amino acids 121-138), 23 (casein amino acids 139-156), 24 (casein amino acids 157-163), 25 (casein amino acids 164-173), 26 (casein amino acids 174-179), 27 (casein amino acids 180-201), 28 (casein amino acids 202-208), 29 (casein amino acids 214-222), 32 (casein amino acids 203-214), and 34 (casein amino acids 159- 173); and (D) those having an annexin precursor include SEQ ID NOs: 18 (casein amino acids
  • Additional constituent peptides of colostrinin include the following peptides with sequence homology to casein: casein alpha S-I derived peptide 16-38 RPKHPIKHQGLPQEVLNENLLRF (SEQ ID NO:35), casein alpha S-I derived peptide 39-52 FVAPFPEVFGKEKV (SEQ ID NO:36), casein alpha S-I derived peptide 195-214 SDIPNPIGSENSEKTTMPLW (SEQ ID NO:37), casein beta derived peptide 199-207 GPVRGPFPI (SEQ ID NO:38), casein beta derived peptide 195-207 EPVLGPVRGPFP1 (SEQ ID NO:39), casein beta derived peptide 199-188 VPYPQRDMPIQ (SEQ ID NO:40), casein beta derived peptide 164-188 SLSQSKVLPVPQKAVPYPQRDMPIQ (SEQ ID NO:41); peptide RPK
  • colostrinin constituent peptides include any of those described in WO 2004/081038, WO 00/75173, WO 02/46211, US Patent Application 2005/0085422, and US Patent Application 2006/0154871.
  • a preferred group of constituent peptides includes:
  • MQPPPLP (SEQ ID NO:1); LQTPQPLLQ VMMEPQGD (SEQ ID NO:2); DQPPDVEKPDLQPFQVQS (SEQ ID NO:3); LFFFLPVVNVLP (SEQ ID NO:4); DLEMPVLPVEPFPFV (SEQ ID NO:5); MPQNFYKLPQM (SEQ ID NO:6); VLEMKFPPPPQETVT (SEQ ID NO:7); LKPFPKLKVEVFPFP (SEQ ID NO:8); and combinations thereof.
  • polypeptides of SEQ ID NOs: 1-46 and other constituent peptides of colostrinin can be in their free acid form or they can be amidated at the C-terminal carboxylate group.
  • the present invention also includes analogs of the polypeptides of SEQ ID NOs: 1-46, which includes polypeptides having structural similarity with SEQ ID NOs: 1 -46.
  • An “analog" of a constituent peptide of colostrinin includes at least a portion of the colostrinin peptide, wherein the portion contains deletions or additions of one, two, three, one to two, one to three, or more contiguous or noncontiguous amino acids, or containing one, two, three, one to two, one to three, or more amino acid substitutions.
  • An “analog” can thus include one, two, three, one to two, one to three, or more additional amino acids at one or both of the N or C terminii of the constituent peptides described herein.
  • Substitutes for an amino acid in the polypeptides of the invention are preferably conservative substitutions, which are selected from other members of the class to which the amino acid belongs.
  • an amino acid belonging to a grouping of amino acids having a particular size or characteristic can generally be substituted for another amino acid without substantially altering the structure of a polypeptide.
  • conservative amino acid substitutions are defined to result from exchange of amino acids residues from within one of the following classes of residues: Class I: Ala, GIy 3 Ser, Thr, and Pro (representing small aliphatic side chains and hydroxyl group side chains); Class II: Cys, Ser, Thr and Tyr (representing side chains including an -OH or -SH group); Class III: GIu, Asp, Asn and GIn (carboxyl group containing side chains): Class IV: His, Arg and Lys (representing basic side chains); Class V: He, VaI, Leu, Phe and Met
  • Class VI Phe, Trp, Tyr and His (representing aromatic side chains).
  • the classes also include related amino acids such as 3Hyp and 4Hyp in Class I; homocysteine in Class II; 2-aminoadipic acid, 2- aminopimelic acid, ( ⁇ -carboxyglutamic acid, ⁇ -carboxyaspartic acid, and the corresponding amino acid amides in Class III; ornithine, homoarginine, N-methyl lysine, dimethyl lysine, trimethyl lysine, 2,3-diaminopropionic acid, 2,4- diaminobutyric acid, homoarginine, sarcosine and hydroxylysine in Class IV; substituted phenylalanines, norleucine, norvaline, 2-aminooctanoic acid, 2- aminoheptanoic acid, statine and ⁇ -valine in Class V; and naphthylalanines, substituted phen
  • the active analogs of a constituent peptide include polypeptides having a relatively large number of proline residues.
  • a "large number" preferably means that a polypeptide includes at least about 15% proline (by number), and more preferably at least about 20% proline (by number).
  • active analogs include more proline residues than any other amino acid.
  • Analogs of constituent peptides of colostrinin include peptides having structural similarity.
  • Structural similarity is generally determined by aligning the residues of the two amino acid sequences to optimize the number of identical amino acids along the lengths of their sequences; gaps in either or both sequences are permitted in making the alignment in order to optimize the number of identical amino acids, although the amino acids in each sequence must nonetheless remain in their proper order.
  • two amino acid sequences are compared using the Blastp program, version 2.0.9, of the BLAST 2 search algorithm, available on the world wide web at ncbi.nlm.nih.gov/gorf/bl2.html.
  • an active analog of a constituent peptide of colostrinin has a structural similarity to colostrinin or one or more of its constituent peptides (preferably, one of SEQ ID NOs: 1-46) of at least about 70% identity, at least about 80% identity, at least about 90% identity, at least about 95% identity, at least about 97% identity, at least about 98% identity, or at least about 99% identity.
  • Colostrinin or any combination of its constituent peptide thereof or active analogs thereof can be derived (preferably, isolated and purified) naturally such as by extraction from colostrum or can be synthetically constructed using known peptide polymerization techniques.
  • the peptides of the invention may be synthesized by the solid phase method using standard methods based on either t- butyloxycarbonyl (BOC) or 9-fluorenylmethoxy-carbonyl (FMOC) protecting groups. This methodology is described by G. B. Fields et al. in Synthetic Peptides: A User's Guide, W.M. Freeman & Company, New York, NY, pp. 77-183 (1992).
  • gene sequence encoding the colostrinin peptides or analogs thereof can be constructed by known techniques such as expression vectors or plasmids and transfected into suitable microorganisms that will express the DNA sequences thus preparing the peptide for later extraction from the medium in which the microorganism are grown.
  • U.S. Patent No. 5,595,887 describes methods of forming a variety of relatively small peptides through expression of a recombinant gene construct coding for a fusion protein which includes a binding protein and one or more copies of the desired target peptide. After expression, the fusion protein is isolated and cleaved using chemical and/or enzymatic methods to produce the desired target peptide. .
  • the peptides used in the methods of the present invention may be employed in a monovalent state (i.e., free peptide or a single peptide fragment coupled to a carrier molecule).
  • the peptides may also be employed as conjugates having more than one (same or different) peptide fragment bound to a single carrier molecule.
  • the carrier may be a biological carrier molecule (e.g., a glycosaminoglycan, a proteoglycan, albumin or the like) or a synthetic polymer (e.g., a polyalkyleneglycol or a synthetic chromatography support).
  • a synthetic polymer e.g., a polyalkyleneglycol or a synthetic chromatography support
  • ovalbumin, human serum albumin, other proteins, polyethylene glycol, or the like are employed as the carrier.
  • Such modifications may increase the apparent affinity and/or change the stability of a peptide.
  • peptide/carrier molecule conjugates may be prepared by treating a mixture of peptides and carrier molecules with a coupling agent, such as a carbodiimide.
  • the coupling agent may activate a carboxyl group on either the peptide or the carrier molecule so that the carboxyl group can react with a nucleophile (e.g., an amino or hydroxyl group) on the other member of the peptide/carrier molecule, resulting in the covalent linkage of the peptide and the carrier molecule.
  • conjugates of a peptide coupled to ovalbumin may be prepared by dissolving equal amounts of lyophilized peptide and ovalbumin in a small volume of water.
  • l-ethyl-3-(3-dimethylamino-propyl)- carboiimide hydrochloride (EDC; ten times the amount of peptide) is dissolved in a small amount of water.
  • EDC l-ethyl-3-(3-dimethylamino-propyl)- carboiimide hydrochloride
  • the EDC solution was added to the peptide/ovalbumin mixture and allowed to react for a number of hours.
  • the mixture may then dialyzed (e g-, into phosphate buffered saline) to obtain a purified solution of peptide/ovalbumin conjugate.
  • Peptide/carrier molecule conjugates prepared by this method may contain about 4 to 5 peptides per ovalbumin molecule.
  • Colostrinin a constituent peptide of colostrinin, an active analog of a constituent peptide of colostrinin, and combinations thereof, may be applied in any application in which an inhibitor of mutagenesis and/or carcinogenesis is desired.
  • colostrinin, a constituent peptide of colostrinin, an active analog of a constituent peptide of colostrinin, and combinations thereof may be applied to cell or administered to a subject to prevent, inhibit, and/or reduce the effects of natural and/or man-made environmental mutagens on the cell or subject.
  • Colostrinin a constituent peptide of colostrinin, an active analog of a constituent peptide of colostrinin, and combinations thereof, may be administered along with additional agents demonstrating anti-mutagenic effects, such as for example, vitamins, thiol compounds, porphyrin derivatives, and polyphenols, the antigenotoxicity of which are well established in various genetic tests.
  • additional agents may or may not act synergistically with colostrinin, a constituent peptide of colostrinin, an active analog of a constituent peptide of colostrinin, or combinations thereof.
  • Colostrinin a constituent peptide of colostrinin, an active analog of a constituent peptide of colostrinin, and combinations thereof, may be administered as an adjunct therapy to the administration of an antibiotic for the treatment of a bacterial infection, reducing the mutation rate in the bacteria cells, and reducing the frequency of the development of antibiotic resistance.
  • Colostrinin a constituent peptide of colostrinin, an active analog of a constituent peptide of colostrinin, and combinations thereof, may be applied as an adjunct therapy to the administration of one or more chemotherapeutic agents in any application in which an inhibitor of mutagenesis and/or carcinogenesis is desired, preventing the development of multi-drug resistant tumor cells due to additional genomic mutations, and lower formation of tumor cells responsible for metastasis.
  • Colostrinin a constituent peptide of colostrinin, an active analog of a constituent peptide of colostrinin, and combinations thereof, may be applied as an adjunct therapy to the administration of one or more chemotherapeutic agent(s) in any application in which an inhibitor of mutagenesis and/or carcinogenesis is desired, preventing the development of mutations in normal cells caused by radio- and chemotherapeutic agents.
  • the present invention also provides a composition that includes one or more active agents (i.e., colostrinin, at least one constituent peptide thereof, or active analog thereof) of the invention and one or more carriers, preferably a pharmaceutically acceptable carrier.
  • the methods of the invention include administering to, or applying to the skin of, a patient, preferably a mammal, and more preferably a human, a composition of the invention in an amount effective to produce the desired effect.
  • the active agents of the present invention are formulated for enteral administration (oral, rectal, etc.) or parenteral administration (injection, internal pump, etc.).
  • the administration can be via direct injection into tissue, interarterial injection, intervenous injection, or other internal administration procedures, such as through the use of an implanted pump, or via contacting the composition with a mucus membrane in a carrier designed to facilitate transmission of the composition across the mucus membrane such as a suppository, eye drops, inhaler, or other similar administration method or via oral administration in the form of a syrup, a liquid, a pill, capsule, gel coated tablet, or other similar oral administration method.
  • the active agents can be incorporated into an adhesive plaster, a patch, a gum, and the like, or it can be encapsulated or incorporated into a bio-erodible matrix for controlled release.
  • the carriers for internal administration can be any carriers commonly used to facilitate the internal administration of compositions such as plasma, sterile saline solution, IV solutions or the like.
  • Carriers for administration through mucus membranes can be any well-known in the art.
  • Carriers for administration oral can be any carrier well-known in the art.
  • the formulations may be conveniently presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Methods may include the step of bringing the active agent into association with a carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active agent into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product into the desired formulations.
  • Formulations suitable for parenteral administration conveniently include a sterile aqueous preparation of the active agent, or dispersions of sterile powders of the active agent, which are preferably isotonic with the blood of the recipient.
  • Isotonic agents that can be included in the liquid preparation include sugars, buffers, and sodium chloride.
  • Solutions of the active agent can be prepared in water, optionally mixed with a nontoxic surfactant.
  • Dispersions of the active agent can be prepared in water, ethanol, a polyol (such as glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, glycerol esters, and mixtures thereof.
  • the ultimate dosage form is sterile, fluid, and stable under the conditions of manufacture and storage.
  • the necessary fluidity can be achieved, for example, by using liposomes, by employing the appropriate particle size in the case of dispersions, or by using surfactants.
  • Sterilization of a liquid preparation can be achieved by any convenient method that preserves the bioactivity of the active agent, preferably by filter sterilization. Preferred methods for preparing powders include vacuum drying and freeze drying of the sterile injectible solutions. Subsequent microbial contamination can be prevented using various antimicrobial agents, for example, antibacterial, antiviral and antifungal agents including parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. Absorption of the active agents over a prolonged period can be achieved by including agents for delaying, for example, aluminum monostearate and gelatin.
  • Formulations of the present invention suitable for oral administration may be presented as discrete units such as tablets, troches, capsules, lozenges, wafers, or cachets, each containing a predetermined amount of the active agent as a powder or granules, as liposomes containing the active agent, or as a solution or suspension in an aqueous liquor or non-aqueous liquid such as a syrup, an elixir, an emulsion, or a draught.
  • the amount of active agent is such that the dosage level will be effective to produce the desired result in the subject.
  • Nasal spray formulations include purified aqueous solutions of the active agent with preservative agents and isotonic agents.
  • Such formulations are preferably adjusted to a pH and isotonic state compatible with the nasal mucous membranes.
  • Formulations for rectal or vaginal administration may be presented as a suppository with a suitable carrier such as cocoa butter, or hydrogenated fats or hydrogenated fatty carboxylic acids.
  • Ophthalmic formulations are prepared by a similar method to the nasal spray, except that the pH and isotonic factors are preferably adjusted to match that of the eye.
  • Topical formulations include the active agent dissolved or suspended in one or more media such as mineral oil, DMSO, polyhydroxy alcohols, or other bases used for topical pharmaceutical formulations.
  • Useful dosages of the active agents can be determined by comparing their in vitro activity and the in vivo activity in animal models. Methods for extrapolation of effective dosages in mice, and other animals, to humans are known in the art; for example, see U.S. Patent No. 4,938,949.
  • the tablets, troches, pills, capsules, and the like may also contain one or more of the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; an excipient such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; a sweetening agent such as sucrose, fructose, lactose or aspartame; and a natural or artificial flavoring agent.
  • a binder such as gum tragacanth, acacia, corn starch or gelatin
  • an excipient such as dicalcium phosphate
  • a disintegrating agent such as corn starch, potato starch, alginic acid and the like
  • a lubricant such as magnesium stearate
  • a sweetening agent such as sucrose, fructose, lactose or aspartame
  • a natural or artificial flavoring agent such
  • Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form.
  • tablets, pills, or capsules may be coated with gelatin, wax, shellac, or sugar and the like.
  • a syrup or elixir may contain one or more of a sweetening agent, a preservative such as methyl- or propylparaben, an agent to retard crystallization of the sugar, an agent to increase the solubility of any other ingredient, such as a polyhydric alcohol, for example glycerol or sorbitol, a dye, and flavoring agent.
  • the material used in preparing any unit dosage form is substantially nontoxic in the amounts employed.
  • the active agent may be incorporated into sustained-release preparations and devices.
  • Active agents can be administered alone or in various combinations to a patient (e.g., animals including humans) as a medication or dietary (e.g., nutrient) supplement in a dose sufficient to produce the desired effect throughout the patient's body, in a specific tissue site, or in a collection of tissues (organs).
  • a patient e.g., animals including humans
  • dietary e.g., nutrient
  • a composition that includes "a" polypeptide refers to a composition that includes one or more polypeptides.
  • amino acid is used herein to refer to a chemical compound with the general formula: NH 2 — CRH — COOH, where R, the side chain, is H or an organic group. Where R is organic, R can vary and is either polar or nonpolar (i.e., hydrophobic). The amino acids of this invention can be naturally occurring or synthetic (often referred to as nonproteinogenic).
  • an organic group is a hydrocarbon group that is classified as an aliphatic group, a cyclic group or combination of aliphatic and cyclic groups.
  • aliphatic group means a saturated or unsaturated linear or branched hydrocarbon group.
  • cyclic group means a closed ring hydrocarbon group that is classified as an alicyclic group, aromatic group, or heterocyclic group.
  • alicyclic group means a cyclic hydrocarbon group having properties resembling those of aliphatic groups.
  • aromatic group refers to mono- or polycyclic aromatic hydrocarbon groups.
  • an organic group can be substituted or unsubstituted.
  • polypeptide and “peptide” are used interchangeably herein to refer to a polymer of amino acids. These terms do not connote a specific length of a polymer of amino acids. Thus, for example, the terms oligopeptide, protein, and enzyme are included within the definition of polypeptide or peptide, whether produced using recombinant techniques, chemical or enzymatic synthesis, or naturally occurring. This term also includes polypeptides that have been modified or derivatized, such as by glycosylation, acetylation, phosphorylation, and the like. The following abbreviations are used throughout the application:
  • Arg Arginine
  • Colostrinin decreases spontaneous and induced mutation frequencies at the hprt locus in Chinese hamster V79 cells
  • Colostrinin a uniform mixture of low-molecular weight, proline-rich polypeptides, induces neurite outgrowth of pheochromocytoma cells, extends the lifespan of diploid fibroblast cells, inhibits beta amyloid-induced apoptosis and resulted in improved cognitive function when administered to Alzheimer's patients.
  • the present example investigated CLN's antimutagenic activity in cells stressed oxidatively or exposed to chemical or physical agents and shows that CLN did not alter cell cycle kinetics and cloning efficiency, while it inhibited the development of spontaneous mutations at the coding region of the hypoxanthine phosphoribosyl- transferase (hprt) gene in Chinese hamster V79 cells.
  • CLN lowered reactive oxygen species (ROS)-induced frequency of cells resistant to 6-thioguanine (6-TG) to nearly background level.
  • ROS reactive oxygen species
  • CLN decreased the frequency of methyl methanesulfonate- or mitomycin C-induced mutations in V79 cells.
  • CLN (at 100, 250, and 500 ng per ml concentrations) decreased UVA-induced mutation frequency.
  • the highest dose of CLN also decreased significantly the number of UVB-induced 6-TG-resistant mutant cells. Similar results were obtained using cell cultures of human origin. Overall, this example shows that CLN significantly lowers the mutation frequency that develops spontaneously or is induced by ROS, chemical and physical agents. CLN itself has no mutagenic activity. Therefore, CLN may be used in human therapies systemically and/or locally for the prevention of diseases associated with sequence alterations in genomic and mitochondrial DNA.
  • CLN is being used in both animal studies and clinical trials. Considering CLN's possible future use in systemic and local applications, it is important to define its toxicity and mutagenicity.
  • the capacity of CLN to prevent/protect cells from a mutagenic effect of reactive oxygen species (ROS) and physical and chemical agents such as ROS generated by glucose oxidase (GOx) (Das et al. J Biol Chem 280: 35272-35280, 2005)
  • ROS reactive oxygen species
  • UVA, UVB, methyl methanesulfonate (MMS), and mitom ⁇ cyn C (MMC) was studied. UVA primarily induces ROS in the presence of endogenous photosensitizers.
  • UVB is absorbed by DNA that leads to direct DNA damage (Pfeifer et al. Mutat Res 571 : 19-31 , 2005).
  • MMS is a monofunctional DNA alkylating agent (Bartsch et al. Mutat Res 110: 181-219, 1983).
  • MMC produces inter- or intra-strand DNA cross-links, single- and double-strand breaks (Waring. Annu Rev Biochem 50: 159-192, 1981), and also triggers ROS generation in mammalian cells (Waring. Annu Rev Biochem 50: 159-192, 1981).
  • V79 hamster lung fibroblast
  • V79 cell cultures have been used since 1970 to study the mutagenic and clastogenic potential of various man-made and environmental agents (reviewed in Bradley et al. Mutat Res 87: 81-142, 1981). Data were confirmed using human bronchial epithelial cells.
  • V79 cells (American Type Culture Collection (ATCC), Rockville, MD, USA) were maintained in Eagle's minimum essential medium
  • EMEM fetal bovine serum
  • FBS fetal bovine serum
  • glutamine 292mg/L
  • streptomycin 100 ⁇ g/ml
  • penicillin 100 U/ml
  • HAT medium containing 5 x 10 '5 M hypoxanthine (Hyp), 4 x 10 "7 M aminopterin, 5 x 10 '6 M thymidine, and stored in numerous replicate vials in liquid nitrogen.
  • A549 bronchial epithelial cells were purchased from ATCC, and cultured in F-12 Kaighn's-modified medium.
  • PD population doubling
  • V79 cells were recovered from liquid nitrogen, cultured in growth medium, containing HAT medium until 90% confluency was attained. The cells were reseeded at a density of 5 x 10 5 cells per dish in growth medium, allowed to proliferate overnight, and then were treated with oxidative stress-inducing agents or exposed to chemical or physical agents. Cells were washed three times with PBS, and 24 hours later monolayers were dissociated and subcultured into 100-mm dishes (5x10 5 cells/ dish) in growth medium containing 6- thioguanine (6-TG; 7 ⁇ g/ml) to identify presumptive mutants or in nonselective medium to measure the plating efficiency.
  • 6- thioguanine 6- thioguanine
  • Colonies of 6-TG-resistant cells were allowed to develop for 6 to 8 days, fixed in 3.7% formalin, and stained with 0.1% crystal violet.
  • the mutation frequency was calculated by determining the number of 6-TG-resistant colonies relative to the number of cells seeded in the selective medium, and normalized for the plating efficiency in the absence of the selective agent (Bradley et al. Mutat Res 87: 81-142, 1981; Albrecht et al., Virology, 230:48- 61, 1997).
  • V79 cells were subcultured at a density of 200 cells per 60-mm Petri-dish. Four hours later, 4 ml of fresh medium was added to parallel cultures containing increasing doses of the test substance. CLN was present for 24 hours, while MMS and GOx treatment was for 1 hour. To determine the effect of UV-irradiation, the medium of the cell culture was removed, and cells were exposed to increasing UV doses. After treatment cells were fed with fresh medium and incubated further for 7 to 10 days. When colonies reached 1 mm in diameter, cells were fixed with 3.7% formalin (30 min) and stained with crystal violet.
  • LDi 0 values were defined as the concentration of agent resulting in 10% inhibition of colony formation. Accurate dose values were estimated from nonlinear regression analysis of concentration- response curves (Boldogh et al. Cancer Res 58: 3950-3956, 1998).
  • Treatment of Cells Cell cultures at appropriate confluency were treated with GOx (20 ng per ml), MMS (1 15 ⁇ M) or MMC (25 ⁇ M) in serum-free medium for 1 hour. At the end of the treatment, cells were washed with PBS to remove the excess toxic compounds and placed under growth medium. CLN at the indicated concentrations was added to the culture media 24 hours prior and 24 hours after treatment with genotoxic agents. In selected experiments, CLN was added either prior to or after treatment.
  • UV-irradiation of Cells Cell cultures (10 cm Petri-dishes) at 50% confluency were irradiated for 24 hours, and then seeded into selection medium.
  • the source of UV-irradiation was UVP, 8W Model UVLMS-38 (Upland CA).
  • the UV doses used in these studies were 4.1 kJ/m 2 for UVB (302 nm) and 87 kJ/m 2 for UVA (365 nm).
  • UVA irradiation was carried out in the presence of the photosensitizer riboflavin (100 ⁇ g per ml). The UV doses were determined with a UVX Digital Radiometer, UVP (Upland, CA) before each treatment. Cell Cycle Analysis.
  • Cell cycle analyses were carried out as previously described (Bresnahan et al. Virology 231 : 239-247, 1997). Briefly, cells were washed in PBS, and collected by sedimentation. Cells were incubated in low salt buffer (3% polyethylene glycol, 5 mg/ml propidium iodine, 0.1% Triton X-100, 4 mM sodium citrate, 100 ⁇ g/ml RNase A) for 20 minutes at 37°C. High salt buffer (3% polyethylene glycol, 5 ⁇ g/ml propidium iodine, 0.1 % Triton X- 100, 400 mM NaCl) was added. The cell cycle stage was determined via cellular DNA content, which was analyzed using a Becton-Dickinson FACScan flow cytometer.
  • low salt buffer 3% polyethylene glycol, 5 mg/ml propidium iodine, 0.1% Triton X-100, 4 mM sodium citrate, 100 ⁇ g/
  • Intracellular ROS Level Changes in intracellular ROS levels were determined as described previously (Boldogh et al. Toxicology 193: 137- 152, 2003). Briefly, the cells were suspended in PBS and incubated with 5 ⁇ M 5(and 6)-carboxy-2', 7'-dichlorodihydrofluorescein diacetate (H 2 DCF-DA; Molecular Probes) for 15 minutes at 37 0 C. The changes in DCF fluorescence were determined by flow cytometry. The mean fluorescence for 12,000 cells from three or more independent experiments was analyzed, and results are expressed as ⁇ SEM. Annexin V Assay.
  • Annexin-PE (BD Biosciences) was added to the cells for 30 minutes, and 7-AAD (2 ⁇ g/ml) was then added before analysis in a FACS can flow cytometer (Becton Dickinson FACscan). The mean fluorescence for 12,000 cells from three or more independent experiments was determined.
  • CLN decreases spontaneous mutation frequency and shows no toxicity.
  • MF mutation frequency
  • CLN has no Effect on Cell Proliferation, Plating Efficiency and Frequency of
  • Results summarized in Fig. 2A show that CLN decreased GOx-induced MF in a dose-dependent manner. For example, 100, 250 and 500 ng per ml CLN decreased MF from 30.7 xlO '6 to 6.7 xlO "6 , 2.6 xl O “6 and 2.5 xl O “6 , respectively (Fig. 2A).
  • CLN protects not only against oxidative stress-induced genotoxic insults, but also decreases UVB- induced mutagenesis, which implies the action of other type(s) of protective mechanism(s).
  • CLN decreases chemical agent-induced mutation frequency.
  • the LD io of MMS was 115 ⁇ M in clonogenic survival assays. Cells at -30% confluence were incubated with CLN (100, 250, 500 ng per ml) for 24 hours followed by MMS (115 ⁇ M) for 1 hour. MMS was removed by washing and the same amount of CLN was added to the corresponding cultures.
  • MMC is extensively used for treatment of diseases, such as malignancies (Bradner et al. Cancer Treat Rev 27: 35-50, 2001) although its mutagenicity is well documented (Davies et al. MutatRes 291 : 117-124, 1993). Therefore, whether CLN would decrease MMC-induced MF was tested. Its LDio was 25 ⁇ M, as determined in preliminary studies. At this concentration, MMC caused an MF of 58.2 ⁇ 5.5 x 10 " 6 cells. When cells were pre- and post-treated with CLN (as in MMS experiments), the number of mutant colonies decreased significantly.
  • Parallel cultures of cells were treated with CLN (250, 500 ng per ml) for 24 hours, and then exposed to LDi 0 (determined in preliminary studies) of GOx (110 ng per ml for 1 hour); UVA (105 kJ per m 2 ), UVB 7.1 kJ per m 2 ) and MMC (53 ⁇ M for 1 hour). Cells were washed, and incubated with CLN-containing growth medium for 52 hours (two PDs). Cells were reseeded in Petri dishes (1 x 10 6 cells per 10 cm dish) in 6-TG containing media. Mutation frequencies were calculated and results are shown in Fig. 5.
  • CLN composed of low-molecular weight, proline-rich polypeptides, induces maturation and differentiation of murine thymocytes, production of cytokines, and neurite outgrowth of pheochromocytoma cells, decreases oxidative stress-mediated activation of c-Jun NH2-terminal kinases, and inhibits beta amyloid-induced apoptosis in cultured cells (Janusz et al. Arch Immunol Ther Exp (Warsz) 41 : 275- 279, 1993, Bacsi et al. Cell MoI Neiirobiol 25: 1 123-1 139, 2005, Stanton et al. Psychogeriat.
  • this example demonstrates that CLN decreases the frequency of mutations developing spontaneously, decreases the frequency of mutations induced by ROS, decreases the frequency of mutations induced by chemical agents, decreases the frequency of mutations induced by UVA, and decreases the frequency of mutations induced by UVB.
  • Oxidative stress is caused by an imbalance between the ROS-generating and -eliminating mechanisms of cells (Lander et al. Nature 381 : 380-381, 1996). Oxidatively damaged lipids and proteins are eliminated by degradation, while DNA is repaired (Mitra et al. Free Radio Biol Med 33: 15-28, 2002).
  • Oxidative stress was produced by GOx 3 a known ROS generator (Nilsson et al. Biochim Biophys Acta 192: 145-148, 1969). This approach provided more consistent results than challenging cells with H 2 O 2 (Das et al. J Biol Chem 280: 35272-35280, 2005).
  • the data show that when CLN was present prior to, during and after oxidative insult of the cells, MF was decreased to nearly background level. Notably, CLN also decreased mutation frequency when it was added prior to or after exposure to ROS.
  • CLN increases the activity of antioxidant enzymes and/or levels of cellular low-molecular weight antioxidants, such as glutathione, which thereby decreases the levels of exogenously introduced ROS, consequently resulting in oxidative damage to DNA.
  • Another possibility is that CLN, by regulating cellular redox, increases the efficacy of the DNA base excision repair (BER) machineries, the major pathways repairing oxidatively damaged DNA (Pines et al. Nucleic Acids Res 33: 4379-4394, 2005, Szczesny ct al. Mech Ageing Dev 125: 755-765, 2004).
  • BER DNA base excision repair
  • UV doses chosen for the experiments in this example are physiologically relevant because they were equivalent to midday sun exposure for 30 and 100 min for UVA and UVB, respectively (Kolari et al. Photodermatol i: 340-345, 1986, Meloni et al. Photochem Photobiol 71 : 681 -690, 2000). These data imply that CLN would likely be suitable for human application to decrease UVA- and UVB-induced cellular damage, and thereby their well-known carcinogenic effects (Setlow et al. Proc Natl Acad Sci USA 90: 6666-6670, 1993, Ley, Cancer Res 57: 3682-3684, 1997). CLN significantly decreased MF induced by DNA-damaging chemical agents.
  • MMS a DNA mono- alkylating agent
  • MGMT O 6 -methylguanine DNA methyl transferase
  • MMC is a DNA cross-linking alkylating agent that, after getting through the cell membrane, is activated by NAD(P)H quinone oxido-reductase, xanthine dehydrogenase, xanthine oxidase, cytochrome p450 reductase and/or cytochrome £» 5 reductase (Collier et al. Life Sci 78: 1499-1507, 2006).
  • NAD(P)H quinone oxido-reductase xanthine dehydrogenase
  • xanthine oxidase cytochrome p450 reductase
  • cytochrome £ 5 reductase
  • CLN biologically active natural compounds
  • This example shows that CLN is potent in decreasing mutation frequency induced spontaneously, decreasing mutation frequency induced ROS, decreasing mutation frequency induced UV radiation, and decreasing mutation frequency induced mono- and bi- functional alkylating agents.
  • one or more of the constituent peptides of colostrinin described herein including, but not limited to MQPPPLP (SEQ ID NO:1); LQTPQPLLQ VMMEP QGD (SEQ ID NO:2); DQPPDVEKPDLQPFQVQS (SEQ ID NO:3); LFFFLPVVNVLP (SEQ ID NO:4); DLEMPVLPVEPFPFV (SEQ ID NO:5); MPQNFYKLPQM (SEQ ID NO:6); VLEMKFPPPPQETVT (SEQ ID NO:7); LKPFPKLKVEVFPFP (SEQ ID NO:8); VVMEV (SEQ ID NO:9); SEQP (SEQ ID NO: 10); DKE (SEQ ID NO:1 1); FPPPK (SEQ ID NO: 12); DSQPPV (SEQ ID NO: 13); DPPPPQS (SEQ ID NO: 14); SEEMP (SEQ ID NO:1); LQTPQPLLQ V
  • VYPFTGPIPN SEQ ID NO: 18
  • SLPQNILPL SEQ ID NO: 19
  • TQTP VVVPPF SEQ ID NO:20
  • LQPEIMGVPKVKETMVPK SEQ ID NO:21
  • HKEMPFPKYPVEPFTESQ SEQ ID NO:22
  • SLTLTDVEKLHLPLPLVQ SEQ ID NO:23
  • SWMHQPP SEQ ID NO:24
  • QPLPPTVMFP SEQ ID NO:25
  • PQSVLS SEQ ID NO:26
  • LS QPKVLP VPQKA VPQRDMPIQ SEQ ID NO:27
  • AFLLYQE SEQ ID NO:28
  • RGPFPILV SEQ ID NO:29
  • ATFNRYQDDHGEEILKSL SEQ ID NO:30
  • VESYVPLFP SEQ ID NO:31
  • FLLYQEPVLGPVR SEQ ID NO:32
  • LNF SEQ ID NO:33
  • SDIPNPIGSENSEKTTMPLW (SEQ ID NO:37), GPVRGPFPI (SEQ ID NO:38), EPVLGPVRGPFPI (SEQ ID NO:39), VPYPQRDMPIQ (SEQ ID NO:40), SLSQSKVLPVPQKAVPYPQRDMPIQ (SEQ ID NO:41), RPKHPIKHQ (SEQ ID NO:42); EPVLGPVR (SEQ ID NO:43); RGPFPIIV (SEQ ID NO:44); PPPPLLPSRPLPPLPPP (SEQ ID NO:45); PPPPPPPPP (SEQ ID NO:46), analogs thereof, and combinations thereof may be assayed for anti-mutagenic effects.
  • the steps may be conducted in any feasible order. And, as appropriate, any combination of two or more steps may be conducted simultaneously.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des procédés pour diminuer la fréquence de mutation dans une cellule, le procédé comprenant la mise en contact de cellules avec de la colostrinine, un peptide constitutif de celle-ci, un analogue actif de ceux-ci ou une combinaison de ceux-ci. Les fréquences de mutation diminuées par le présent procédé comprennent les mutations spontanées et les mutations induites par les espèces à oxygène réactif (ROS), le rayonnement UVA, le rayonnement UVB, les agents chimiques et les agents physiques.
PCT/US2007/017112 2006-07-31 2007-07-31 Utilisation de la colostrinine, peptides constitutifs de celle-ci, et leurs analogues comme agents anti-mutagéniques WO2008016604A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83443306P 2006-07-31 2006-07-31
US60/834,433 2006-07-31

Publications (2)

Publication Number Publication Date
WO2008016604A2 true WO2008016604A2 (fr) 2008-02-07
WO2008016604A3 WO2008016604A3 (fr) 2008-06-26

Family

ID=38997678

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/017112 WO2008016604A2 (fr) 2006-07-31 2007-07-31 Utilisation de la colostrinine, peptides constitutifs de celle-ci, et leurs analogues comme agents anti-mutagéniques

Country Status (1)

Country Link
WO (1) WO2008016604A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009138762A2 (fr) * 2008-05-15 2009-11-19 Regen Therapeutics Plc Utilisation thérapeutique de peptides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037851A2 (fr) * 2002-10-22 2004-05-06 Board Of Regents The University Of Texas System Utilisation de colostrinine, peptides constitutifs de celle-ci, et analogues de celle-ci utilises en tant que modulateurs de molecules de signalisation intracellulaire et inhibiteurs de l'apoptose

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037851A2 (fr) * 2002-10-22 2004-05-06 Board Of Regents The University Of Texas System Utilisation de colostrinine, peptides constitutifs de celle-ci, et analogues de celle-ci utilises en tant que modulateurs de molecules de signalisation intracellulaire et inhibiteurs de l'apoptose

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 2006, BACSI ATTILA ET AL: "Colostrinin decreases spontaneous and induced mutation frequencies at the hprt locus in Chinese hamster V79 cells." XP002477053 Database accession no. NLM17024966 & JOURNAL OF EXPERIMENTAL THERAPEUTICS & ONCOLOGY 2006, vol. 5, no. 4, 2006, pages 249-259, ISSN: 1359-4117 *
GLADKEVICH ET AL: "Proline-rich polypeptides in Alzheimer's disease and neurodegenerative disorders - Therapeutic potential or a mirage?" PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, OXFORD, GB, vol. 31, no. 7, 28 August 2007 (2007-08-28), pages 1347-1355, XP022215883 ISSN: 0278-5846 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009138762A2 (fr) * 2008-05-15 2009-11-19 Regen Therapeutics Plc Utilisation thérapeutique de peptides
WO2009138762A3 (fr) * 2008-05-15 2010-04-01 Regen Therapeutics Plc Utilisation thérapeutique de peptides

Also Published As

Publication number Publication date
WO2008016604A3 (fr) 2008-06-26

Similar Documents

Publication Publication Date Title
Acuna Castroviejo et al. Melatonin-mitochondria interplay in health and disease
CA2138122C (fr) Preparations pharmaceutiques pour l'inhibition de tumeurs associees a l'adenocarcinome de la prostate, ainsi qu'au cancer du sein et de l'estomac
CN110062621B (zh) 氨基酸组合物及其用途
EP3230318B1 (fr) Combinaisons d'inhibiteurs de points de contrôle immunitaires
Impicciatore et al. Nutlins and ionizing radiation in cancer therapy
WO2010033771A2 (fr) Modulateurs de la fonction hsp70/dnak et procedes d'utilisation associes
Gong et al. HERG K+ channel related chemosensitivity to sparfloxacin in colon cancer cells
CN112601513B (zh) 治疗眼部疾病的药物
EP1641820B1 (fr) Peptide derive de rasgap pour tuer selectivement des cellules cancereuses
Pena-Altamira et al. Release of soluble and vesicular purine nucleoside phosphorylase from rat astrocytes and microglia induced by pro-inflammatory stimulation with extracellular ATP via P2X7 receptors
US20070065399A1 (en) Use of colostrinin, constituent peptides thereof, and analogs thereof as modulators of intracellular signaling molecules
KR101454866B1 (ko) 항암 약물로에 대한 무반응성 종양의 치료 및 화학증감을 위한 ｃｋ2 저해제의 용도
Dong et al. Targeted antimicrobial peptide delivery in vivo to tumor with near infrared photoactivated mesoporous silica nanoparticles
Chen et al. Platonin induces autophagy-associated cell death in human leukemia cells
EP2155237B1 (fr) Glycosylasparaginase pour le traitement de cancers
EP1123097B1 (fr) Composition pharmaceutique contenant de la decursine
WO2008016604A2 (fr) Utilisation de la colostrinine, peptides constitutifs de celle-ci, et leurs analogues comme agents anti-mutagéniques
KR20200023991A (ko) 에리스로포이에틴 유래 펩티드를 함유하는 세포증식 촉진용 조성물
Kataoka, JS Murley, R. Patel, DJ Grdina Cytoprotection by WR-1065, the active form of amifostine, is independent of p53 status in human malignant glioma cell lines
Yan et al. Nintedanib ameliorates osteoarthritis in mice by inhibiting synovial inflammation and fibrosis caused by M1 polarization of synovial macrophages via the MAPK/PI3K‐AKT pathway
Lee et al. Antioxidant effect of melatonin in human retinal neuron cultures
US20050042300A1 (en) Use of colostrinin, constituent peptides thereof, and analogs thereof as inhibitors of apoptosis and other cellular damage
TW201722457A (zh) 短合成胜肽及其用途
US6066665A (en) Combination of cis-4-hydroxy-L-proline and N-methyl-cis-4-hydroxy-L-proline for use as a therapeutic agent, in particular in cancer treatment
Ostler et al. Toxicity of Poly I. Poly C for Rabbit Eyes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07836370

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

NENP Non-entry into the national phase in:

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07836370

Country of ref document: EP

Kind code of ref document: A2